title: Perindopril and candesartan comparative efficacy and safety in type II diabetic hypertensive patients.
authors.forename: G
authors.initials: G
authors.lastname: Derosa
authors.forename: A F G
authors.initials: AF
authors.lastname: Cicero
authors.forename: A
authors.initials: A
authors.lastname: Mugellini
authors.forename: L
authors.initials: L
authors.lastname: Ciccarelli
authors.forename: R
authors.initials: R
authors.lastname: Fogari
mesh_terms: D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology*; D008297:Male; D020913:Perindopril / Q000009:adverse effects / Q000627:therapeutic use*; D013777:Tetrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D013777:Tetrazoles; C081643:candesartan; D020913:Perindopril